Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year High – What’s Next?

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) reached a new 52-week high on Wednesday . The company traded as high as $43.66 and last traded at $44.00, with a volume of 129530 shares trading hands. The stock had previously closed at $39.90.

Analysts Set New Price Targets

ORKA has been the topic of several recent research reports. UBS Group started coverage on Oruka Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target on the stock. Barclays upped their price objective on Oruka Therapeutics from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, March 13th. Piper Sandler began coverage on Oruka Therapeutics in a report on Thursday, December 18th. They set an “overweight” rating and a $75.00 target price on the stock. Leerink Partners boosted their target price on Oruka Therapeutics from $58.00 to $86.00 and gave the stock an “outperform” rating in a research report on Monday, March 16th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, March 13th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $59.60.

Oruka Therapeutics Price Performance

The company has a market capitalization of $2.25 billion, a P/E ratio of -24.44 and a beta of -0.38. The business’s 50-day moving average price is $35.12 and its two-hundred day moving average price is $29.13.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. Research analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Insider Transactions at Oruka Therapeutics

In other news, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the sale, the chief executive officer owned 927,309 shares of the company’s stock, valued at $38,297,861.70. This trade represents a 0.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Joana Goncalves sold 7,641 shares of Oruka Therapeutics stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $40.91, for a total value of $312,593.31. Following the transaction, the insider owned 33,377 shares in the company, valued at $1,365,453.07. This trade represents a 18.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 23,765 shares of company stock valued at $849,575. Insiders own 24.69% of the company’s stock.

Institutional Trading of Oruka Therapeutics

A number of large investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of Oruka Therapeutics in the second quarter valued at approximately $31,000. BNP Paribas Financial Markets boosted its holdings in shares of Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after buying an additional 2,306 shares during the period. Royal Bank of Canada increased its position in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the fourth quarter worth $37,000. 56.44% of the stock is owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.